Journal: Frontiers in Cell and Developmental Biology

Article Title: Single cell Raman spectroscopic profiles predict treatment responses in patients with de novo acute myeloid leukemia

doi: 10.3389/fcell.2026.1767226

Figure Lengend Snippet: Structure diagram of Raman spectral system.

Article Snippet: A 532 nm deep-cutoff rapid edge Raman Rayleigh rejection filter (Edmund Optics) was used to suppress Rayleigh background scattering prior to the signal entering the spectrometer’s 30–100 μm wide entrance slit.

Techniques:

Journal: Frontiers in Cell and Developmental Biology

Article Title: Single cell Raman spectroscopic profiles predict treatment responses in patients with de novo acute myeloid leukemia

doi: 10.3389/fcell.2026.1767226

Figure Lengend Snippet: Mean Raman spectra of AML cells from CR and NR patients. (A) Mean Raman spectrum (blue solid line)and associated standard deviation (shaded band) for the complete response group (CR; n = 335). (B) Mean Raman spectrum (red solid line) and associated standard deviation (shaded band) for the non-remission group (NR; n = 322). (C) Differential spectrum derived from the mean Raman spectra of CR and NR groups. Statistically significant peaks in the differential spectrum are highlighted with background colors corresponding to primary biomolecular assignments: green (nucleic acids), blue (amino acids), and orange (lipids).

Article Snippet: A 532 nm deep-cutoff rapid edge Raman Rayleigh rejection filter (Edmund Optics) was used to suppress Rayleigh background scattering prior to the signal entering the spectrometer’s 30–100 μm wide entrance slit.

Techniques: Standard Deviation, Derivative Assay

Journal: Frontiers in Cell and Developmental Biology

Article Title: Single cell Raman spectroscopic profiles predict treatment responses in patients with de novo acute myeloid leukemia

doi: 10.3389/fcell.2026.1767226

Figure Lengend Snippet: Raman spectral PCA-LDA cluster analysis of different reaction types in newly diagnosed AML patients. (A) The first three PC scores in PCA spatial scatter cluster analysis diagram. (B) The PC loads for the first three principal components. (C) Scatter cluster analysis diagram of LDA. (D) ROC curve of the PCA-LDA model.

Article Snippet: A 532 nm deep-cutoff rapid edge Raman Rayleigh rejection filter (Edmund Optics) was used to suppress Rayleigh background scattering prior to the signal entering the spectrometer’s 30–100 μm wide entrance slit.

Techniques:

Journal: Frontiers in Cell and Developmental Biology

Article Title: Single cell Raman spectroscopic profiles predict treatment responses in patients with de novo acute myeloid leukemia

doi: 10.3389/fcell.2026.1767226

Figure Lengend Snippet: Analysis of Raman spectra from AML cells of newly diagnosed patients with different treatment responses using MCR-ALS. (A) Decomposition into four spectral components. (B) Concentration values corresponding to the four components. (C) Histograms of the average abundance of the three components. P-values obtained from t-tests to determine if there are significant differences between the two groups. * P < 0.05, *** P < 0.001 (unpaired t-test or mann-whitney test).

Article Snippet: A 532 nm deep-cutoff rapid edge Raman Rayleigh rejection filter (Edmund Optics) was used to suppress Rayleigh background scattering prior to the signal entering the spectrometer’s 30–100 μm wide entrance slit.

Techniques: Concentration Assay, MANN-WHITNEY

Journal: JHLT Open

Article Title: Three-year outcomes with the use of dual non-invasive rejection surveillance after heart transplantation

doi: 10.1016/j.jhlto.2025.100456

Figure Lengend Snippet: Number of Biopsies Performed in the First 3 Years Post Transplant. GEP: gene expression profiling, ddcfDNA: donor-derived cell-free DNA.

Article Snippet: Surveillance in this cohort was via EMB until postoperative day 55; thereafter rejection monitoring with GEP (Allomap, CareDx, Brisbane, CA) was offered at the discretion of treating physicians and in the absence of clinical suspicion for rejection.

Techniques: Gene Expression, Derivative Assay

Journal: JHLT Open

Article Title: Three-year outcomes with the use of dual non-invasive rejection surveillance after heart transplantation

doi: 10.1016/j.jhlto.2025.100456

Figure Lengend Snippet: Survival at 3 Years Post Transplant by Surveillance Cohort. GEP: gene expression profiling, ddcfDNA: donor-derived cell-free DNA.

Article Snippet: Surveillance in this cohort was via EMB until postoperative day 55; thereafter rejection monitoring with GEP (Allomap, CareDx, Brisbane, CA) was offered at the discretion of treating physicians and in the absence of clinical suspicion for rejection.

Techniques: Gene Expression, Derivative Assay

Journal: JHLT Open

Article Title: Three-year outcomes with the use of dual non-invasive rejection surveillance after heart transplantation

doi: 10.1016/j.jhlto.2025.100456

Figure Lengend Snippet: a. ACR Free Survival at 3 Years Post Transplant by Surveillance Cohort. ACR: acute cellular rejection (ISHLT 2R or greater), GEP: gene expression profiling, ddcfDNA: donor-derived cell-free DNA. b. AMR Free Survival at 3 Years Post Transplant by Surveillance Cohort. AMR: antibody mediated rejection, GEP: gene expression profiling, ddcfDNA: donor-derived cell-free DNA.

Article Snippet: Surveillance in this cohort was via EMB until postoperative day 55; thereafter rejection monitoring with GEP (Allomap, CareDx, Brisbane, CA) was offered at the discretion of treating physicians and in the absence of clinical suspicion for rejection.

Techniques: Gene Expression, Derivative Assay

Journal: JHLT Open

Article Title: Three-year outcomes with the use of dual non-invasive rejection surveillance after heart transplantation

doi: 10.1016/j.jhlto.2025.100456

Figure Lengend Snippet: Ejection Fraction by Surveillance Cohort. LVEF: Left Ventricular Ejection Fraction, GEP: gene expression profiling, ddcfDNA: donor-derived cell-free DNA.

Article Snippet: Surveillance in this cohort was via EMB until postoperative day 55; thereafter rejection monitoring with GEP (Allomap, CareDx, Brisbane, CA) was offered at the discretion of treating physicians and in the absence of clinical suspicion for rejection.

Techniques: Gene Expression, Derivative Assay